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Cyclin-Dependent Kinase 1 CDK1 is the major M-phase kinase known also as the M-phase 
Promoting Factor or MPF. Studies performed during last decade have shown many details of 
how CDK1 is regulated and also how it regulates the cell cycle progression. Xenopus laevis 
cell- free extracts were widely used to elucidate the details and to obtain a global view of the 
role of CDK1 in M-phase control. CDK1 inactivation upon M-phase exit is a primordial 
process leading to the M-phase/interphase transition during the cell cycle. Here we discuss 
two closely related aspects of CDK1 regulation in Xenopus laevis cell- free extracts: firstly, 
how CDK1 becomes inactivated and secondly, how other actors, like kinases and phophatases 
network and/or specific inhibitors cooperate with CDK1 inactivation to assure timely exit 
from the M-phase. 
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1. Introduction 
The cell cycle regulation comprises a network of numerous kinases and phosphatases. CDK1 
is a major kinase necessary both for the S-phase and M-phase progression. Identification at 
the end of XX century of the CDK1 as a major regulator of the cell cycle made the 
understanding of its own regulation a fascinating topic. The use of Xenopus laevis cell- free 
extracts has had a large impact on these studies. 
CDK1 belongs to the family of Cyclin-Dependent Kinases (CDKs). It has been the 
first CDK described in yeast (as a product of cdc2 or cdc28 gene depending on species) and 
human (called p34cdc2). The name of CDKs comes from the association of these kinases with 
the regulatory subunits called cyclins. Similarly to all other kinases CDK1 has in its amino-
terminal domain a xGxPxxxxREx sequence (where x represents any amino-acid). This 
conserved region corresponds to a cyclin binding domain [1]. There are twenty one CDK-
coding genes in the human genome [2]. However, only a few of them are involved in cell 
cycle regulation. In Xenopus laevis oocytes and early embryos a handful of CDKs are 
expressed (CDK1, CDK2, CDK5, CDK9; our unpublished data). Two major CDKs taking 
part in cell cycle regulation are CDK1 and CDK2. Only CDK1 seems to be involved in M-
phase regulation, while CDK2 is a major player in S-phase progression. The similarity in 
three-dimensional structure of these two kinases helps to understand some aspects of their 
regulation. 
CDK1 activity picks only for a very short period of time upon G2/M transition and 
falls down rapidly at the M-phase exit. The structure of CDK1 is bilobate, similar to the cyclic 
AMP-dependent protein kinase, but contains a unique helix- loop segment that interferes with 
ATP and protein substrate binding. In its monomeric inactive form, CDK1 binds to the ATP 
in a conformation, which prevents a nucleophilic attack by hydroxyl substrate on the β-γ 
phosphate bridge of ATP [3].   
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 Cyclins, the regulatory subunits of CDKs, are encoded by at least 15 different genes in 
human genome [2]. Only some of them are expressed in oocytes and early embryos of 
Xenopus laevis. B-type cyclins are main regulators of CDK1. In Xenopus laevis early 
developmental stages five of B-type cyclins (B1-B5) were identified [4]. B1 and B2 cyclins 
play a major role in M-phase regulation in Xenopus laevis since they are associated with the 
majority of CDK1. Upon M-phase exit cyclins are degraded sequentially beginning from 
cyclin B1 and ending with cyclin B5. This sequential degradation of cyclins reflects 
inactivation of successive parts of CDK1. Thus just a brief look at the composition and 
metabolism of CDK1/cyclin B complexes illustrates the complexity of the system, and this is 
just the tip of the iceberg. 
 
2. M-phase control in Xenopus laevis oocytes via MPF, CSF and calcium signalling 
Amphibian oocytes have been excellent model system allowing the discovery of the basic 
principles of M-phase regulation. Most of the molecules regulating M-phase entry, maintaining 
and exit were identified with the help of the amphibian experimental model. The enzymatic 
complex of CDK1 and cyclin B is the universal regulator of the M-phase. It was first 
discovered as an activity called Maturation Promoting Factor (MPF) by Masui and Markert in 
1971 [5]. MPF drives both meiotic and mitotic cell cycle via M-phase entry induction. Masui 
and Markert [1] discovered the MPF activity in experiments involving a cytoplasmic transfer 
between mature and immature oocytes of Rana pipiens and Xenopus laevis. Such a transfer 
invariably induced resumption of meiotic maturation, i.e. M-phase entry in G2-arrested 
immature oocytes. Initially, the MPF activity was called a Maturation Promoting Factor 
because of its ability to induce maturation upon injection into immature oocytes. However 
further studies have shown that the very same factor induces also the mitotic M-phase. Thus 
the name of Maturation Promoting Factor was changed to M-phase Promoting Factor. Soon 
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after, the MPF was shown to have an M-phase- inducing activity regardless of the species. This 
suggested the key role of this molecule in the induction of the M-phase of cell cycle in all 
eukaryotic cells. After numerous efforts,  MPF was identified as a complex of Cyclin-
Dependent Kinase 1 (CDK1) and its regulatory subunit cyclin B [6-9]. 
 Masui and Markert [5] demonstrated the presence of another factor that stabilized MPF 
in MII-arrested oocytes. They called it the CSF for CystoStatic Factor. Identification of the 
molecular identity of CSF took more time and energy than identification of MPF. The key 
player in the CSF pathway was discovered recently as a protein called Early mitotic inhibitor 2 
(Emi2) [10-13]. Emi2 arrests the Ubiquitin/Proteasome System (UPS) by an inhibitory 
association with APC/CCdc20 ubiquitin ligase necessary for cyclin B ubiquitination and 
targeting the CDK1/cyclin B to proteasomes where cyclin B becomes degraded.  Thus, CSF 
holds APC/C in an inactive state assuring MII-arrest in oocytes, and Emi2 is the most 
downstream effector.  
Amphibian oocytes, similarly to the majority of other vertebrate oocytes, are ovulated 
in MII-arrested state. Mos/…/ERK2 MAP kinase pathway stabilizes Emi2 during this period. 
The stabilization of Emi2 is achieved via phosphorylation on Thr 336, Ser 342 and Ser 344 by 
the most downstream enzyme of ERK2 MAP kinase pathway, the Rsk90 kinase. These 
phosphorylations promote Emi2-PP2A interaction and thus antagonize Emi2 phosphorylation 
by CDK1/cyclin B [14]. Other residues, namely T545 and T551, are phosphorylated by CDK1/ 
cyclin B [15]. These phosphorylations are removed by protein phosphatase 2A (PP2A) 
assuring the turnover of Emi2 phosphorylation during the oocyte MII-arrest (Fig. 1).  
Upon fertilization, the spermatozoon entering the oocyte induces a burst of free calcium 
in the ooplasm. The calcium signaling plays a major role in triggering the developmental 
program of the embryo. The rapid increase in calcium concentration inactivates CSF. The first 
step is activation of calcium-dependent kinase 2 (CaMK2), which phosphorylates Emi2. This 
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turns Emi2 into a substrate for Plk1, the kinase which is already active in MII oocytes before 
fertilization, but unable to phosphorylate Emi2 before it becomes modified by CaMK2 (Fig. 1). 
The double CaMK2- and Plk1-mediated modification of Emi2 following fertilization makes 
this protein recognizable by SCF-TRCP ubiquitin ligase. SCF-TRCP triggers Emi2 
polyubiquitination followed by its proteasome-dependent degradation and disappearance from 
the ooplasm. This complex process is necessary to remove the CSF activity and to release the 
MII-arrest of oocytes upon fertilization via APC/C activation and triggering cyclin B 
polyubiquitination [10-12]. 
Despite the major role of the Mos…/ERK2 MAP kinase pathway resulting in Emi2 
stability other alternative CSF pathways seem also involved in MII arrest induction and 
maintenance. For example CDK2/cyclin E pathway was shown to induce a CSF-like arrest in 
Xenopus laevis cell- free extracts [16]. A checkpoint kinase Mps1 (Monopolar spindle 1) is 
necessary for this action of CDK2/cyclin E [16]. Further details of the role of this alternative 
CSF pathway and especially its elimination upon oocyte activation remain unknown. 
The CSF inactivation is not the only effect of the rise in calcium concentration upon 
fertilization. The calcium burst also triggers a transient activation of a phosphatase called 
calcineurin [17, 18], which is absolutely necessary for oocyte activation. However, it is 
unknown whether calcineurin acts on CDK1 or on some of its substrates. Nevertheless, these 
results pinpoint the network of kinases and phosphatases involved in phosphorylation and 
dephosphorylation events of numerous proteins as major mean to regulate the cell cycle 
transition necessary to initiate the embryo development.  
 
3. CDK1 inactivation without cyclin B degradation 
Proteolytic degradation of cyclin B via UPS plays a major role in cell cycle regulation. Its 
perturbation disorganizes the cell cycle progression [19-21]. Inhibition of the proteolytic 
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activity of proteasome with inhibitors like MG115, MG132 or ALLN arrests cells in M-phase 
with high cyclin B content and equally high CDK1 activity. The same inhibitors block also 
cyclin B degradation in Xenopus laevis cell- free extracts, however, they neither arrest CDK1 
inactivation nor provoke the M-phase-arrest [22-24]. This important difference between the 
reaction of intact cells and cell- free extracts strongly suggests that CDK1 inactivation 
proceeds without cyclin B degradation at least in Xenopus laevis oocytes and embryo extracts. 
The reason for such a different reaction of intact cells and cell- free extract to proteasome 
inhibition remains unclear. It seems reasonable to speculate that in the case of somatic cells 
some up-stream substrate of proteasome pathway must be degraded before cyclin B could be 
targeted for degradation. In this case the proteosome inhibition would inhibit cyclin B 
degradation indirectly, via action of remaining up-stream substrate of UPS.  However, the 
identity of a potential UPS substrate conditioning cyclin B degradation in intact cells remains 
unknown. 
The first step in cyclin B degradation is its polyubiquitination by APC/C ubiquitin 
ligase (Fig. 2). This process takes place when cyclin B is still associated with CDK1. Thus, 
APC/C-mediated polyubiquitination targets to the proteasome not only cyclin B but the whole 
complex, which is still active when cyclin B is in the polyubiquitinated state. The proteasome 
induces or catalyses the dissociation of cyclin B from its CDK1 partner. Nishiyama and 
colleagues [22] have shown that the activity of the 26S proteasome invo lved in cyclin B 
dissociation from CDK1 is associated with its 19S regulatory subunit. It seems that the lid of 
the proteasome could be involved in this process. The 19S subunits of proteasome may also 
deubiquitinate, and concomitantly denature cyclin B before it becomes loaded into the 20S 
proteasome catalytic chamber. This hypothetical modification of cyclin B may, as a side 
effect, trigger its dissociation from CDK1. Takeo Kishimoto’s group named the dissociating 
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activity of the proteasome a “non-proteolytic activity” to distinguish it from the classical 
proteolytic activity [22]. 
The APC/C activity is itself positively regulated in large part by CDK1/cyclin B-
dependent phosphorylations of its numerous subunits [25, 26]. These phosphorylations trigger 
cyclin B polyubiquitination, dissociation from CDK1 and degradation resulting in CDK1 
inactivation. In addition, the substrate specificity of APC/C changes during mitosis, due to the 
switch in its regulatory subunit, from Cdc20 (Fizzy) to Cdh1 (Fizzy-related). This switch is 
possible after Cdc20 poluybiquitination by APC/C and its subsequent degradation. Thus, 
CDK1/cyclin B indirectly regulates itself via controlling APC/C activity at least at two 
different levels, which in turn determines the stability of cyclin B (reviewed  in [27, 28]).   
 
4. CDK1 inactivation is inhibited by interference with cyclin B polyubiquitination 
Ubiquitin is a highly evolutionary conserved small (76 amino acids) polypeptide. Its 
COOH terminus is covalently linked to lysine residues of a substrate (e.g. cyclin B) via an 
isopeptide bond (for a review see [30]). Polyubiquitination proceeds via multiple rounds of 
ubiquitination during which the COOH terminus of a new ubiquitin molecule forms an 
isopeptide bond with the lysine residue of ubiquitin previously attached to the substrate. This 
process is mediated by three sequentially acting enzymes (E1, E2 and E3, the last being an 
ubiquitin ligase). Lysine 48 of ubiquitin molecule is one of the major residues involved in 
polyubiquitination, mediating subsequent targeting of substrates to the proteasome. However, 
all seven lysine residues present within the molecule of ubiquitin are able to form isopeptide 
bonds [29-31]. A mutation of lysine 48 (K48) to arginine (R) severely affects the process of 
polyubiquitination [32,33]. Such ubiquitin mutant (UbiK48R) was used to perturb 
ubiquitination of proteins during the M-phase in the cell- free mitotic extracts upstream from 
the inhibition of the proteolytic activity of the proteasome. The interference with the 
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polyubiquitination pathway via UbiK48R arrests cyclin B dissociation from CDK1 and its 
degradation [34]. Therefore, the polyubiquitination pathway appears to be necessary for the 
targeting of cyclin B complexed with CDK1 to the proteasome. This in turn results in the 
maintenance of high activity of CDK1 and keeping the extract in the M-phase. Thus UPS 
inhibition at the level of plyubiquitination and not at the level of the proteasome proteolytic 
activity inhibits effectively CDK1 inactivation. This points to the importance of cyclin B 
dissociation from CDK1 and not the degradation of cyclin B. 
 
5. Alternative pathways to inactivate CDK1 
 
5A. Dephosphorylation of CDK1 threonine 161 
The phosphorylation of threonine 161 residue of CDK1 is necessary for activation of CDK1. 
Thus, the dephosphorylation of this site may inactivate CDK1 independently of cyclin B 
dissociation and proteolysis [35,36]. The dephosphorylation is catalyzed by the okadaic acid 
(OA)-sensitive type 2C protein phosphatases (PP2Cs) [36]. The comparison of the dynamics of 
CDK1 inactivation with the dynamics of CDK1 Thr161 dephosphorylation upon M-phase exit 
has shown that the latter follows CDK1 inactivation [24]. The detailed analysis of the 
interaction between CDK1 and cyclin B2 (one of five cyclins B potentially present in Xenopus 
laevis early embryos) upon M-phase exit revealed that the dissociation of cyclin B2 from 
CDK1 perfectly correlates with the dynamics of CDK1 inactivation and not with CDK1 
threonine 161 dephosphorylation [24]. Thus, CDK1 threonine 161 residue dephosphorylation 
is a relatively late step in CDK1 inactivation and perhaps plays a role in the ultimate switching 
off of the CDK1, thus protecting the cell against unscheduled and premature reactivation of the 




5B. Transient inhibitory phosphorylation of CDK1 on threonine 14 and tyrosine 15  
A study in Xenopus laevis cell- free extracts has shown that a transient phosphorylation of 
CDK1 on tyrosine 15 (and most probably on threonine 14) could also participate in CDK1 
inactivation. D’Angiolella and colleagues have shown that in cycling cell- free extracts the 
cyclin B1-associated histone H1 kinase activity diminishes more rapidly than the level of 
cyclin B1 protein [37]. This was not the case for cyclin A-associated activity and the 
diminution of the level of cyclin A protein. Detailed analysis of M-phase exiting extracts both 
during mitosis and meiosis (CSF extract treated with calcium) has revealed a transient re-
phosphorylation of cyclin B-associated CDK1 on tyrosine 15 following the initial drop in 
CDK1 inactivation. This short lasting increase in tyrosine 15 phosphorylation could be 
mediated by a transient increase in association of CDK1 with Wee1 kinase catalysing the 
reaction of phosphorylation at this site. However, another study has shown that CDK1 
dephosphorylation at tyrosine 15 precedes the kinase inactivation [38] (Fig. 3). Thus, it is not 
entirely clear to what extend this kind of regulation influences the dynamics of CDK1 
inactivation. 
 
5C. Specific inhibitors may participate in CDK1 inactivation 
Data from yeast and HeLa cells suggest that the specific inhibitors could also be involved in 
CDK1 inactivation upon mitotic exit. Cdc6 protein, well know as a key S-phase regulator, 
could play this role [39, 40] (Fig. 3). There is no data supporting such a role of Cdc6 in 
Xenopus laevis cells. However, since Cdc6 was shown to inhibit CDK1 both in yeast and in 
human cells it seems possible that it also plays the same role in amphibians. CDK1 inhibition 
specifically during the M-phase exit may lead, together with the transient CDK1 
phosphorylation on tyrosine 15, to more rapid and more effective inhibition of CDK1. 
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5D. Cooperation of CDK2 and PKA in CDK1 inactivation 
The next alternative pathway of CDK1/cyclin B inactivation implies the participation of 
CDK2. It was shown in 2001 that CDK2/cyclin E enables to maintain the high CDK1/cyclin B 
activity during mitosis in Xenopus laevis cell- free extract [41]. Premature inactivation of 
CDK2 during the mitotic M-phase induces an increase in protein kinase A (PKA) activity and 
speeds up CDK1/cyclin B inactivation and cyclin B degradation. Thus, CDK2/cyclin E seems 
to be coupled with PKA activity in assuring a correct timing of CDK1/cyclin B inactivat ion 
and the M-phase exit. However, it remains unknown how CDK2 and PKA act in concert on 
CDK1 and cyclin B degradation pathway.  
  Crystallographic studies of another CDK2 enzymatic complex, namely CDK2/cyclin A 
that has fundamental role in S-phase regulation, have shown details of the mechanism 
underlying inactivation of this kinase [2, 42]. CDK1/cyclin B complex has never been studied 
with such accuracy. As the two complexes are closely related the mechanism proposed for 
CDK2 may also apply to CDK1. The active site of CDK1 could undergo conformational 
changes in its PSTAIRE helix and T-loop upon the dissociation of cyclin B, as it happens with 
CDK2 upon dissociation of cyclin A. Such a conformational change prevents proper 
interaction of the enzyme with ATP and inactivates the kinase [2, 42]. The cyclin subunit 
determines substrate specificity of CDKs (reviewed in [43]). Thus, the loss of cyclin subunit 
should be immediately followed by efficient inactivation of CDK1 to protect the cell against 
possible phosphorylation of undesired substrates. A part of this job may be performed by the 
transient inhibitory phosphorylation of tyrosine 15. Another possibility to eliminate unspecific 
activity of cyclin-free CDK1 would be a direct inhibition via its association with a specific 
inhibitor, for instance Cdc6. 
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6. Kinase/phosphatase network upon M-phase exit 
In HeLa cells CDK1 inactivation is not sufficient to assure the successful transition to 
interphase. The efficient transition to interphase requires a phosphatase activity (or activities) 
dephosphorylating CDK1 mitotic substrates [44]. The activation of these phosphatases is 
clearly proteasome-dependent, but independent of cyclin B degradation. PP2A was shown to 
be the major phosphatase dephosphorylating CDK1 substrates in interphase Xenopus laevis 
eggs extract [45]. PP2A is a heterotrimer composed of the catalytic C-, scaffolding A- and 
regulatory B-type subunits represented by different isoforms. The B-type subunits are 
responsible for the substrate-specificity of the whole complex [46]. Mochida and colleagues 
[45] have shown that PP2A containing the B55 subunit is the major phosphatase controlling 
the exit from the M-phase via dephosphorylation of CDK1 phospho-substrates. It was proposed 
that the newly discovered Greatwall kinase could play a role of a phosphatase suppressor [47]. 
Greatwall kinase was discovered in a screen for Drosophila mutants defective in chromosome 
condensation [48]. Greatwall is a ubiquitous evolutionarily conserved protein kinase, known in 
humans as MAST-L kinase, belonging to the AGC family of Ser/Thr kinases [49]. Depletion of 
this kinase from M-phase extracts induced activation of an okadaic-sensitive phosphatase that 
acts on CDK1 substrates and on the mitotic exit. Addition of this kinase to interphase extracts 
inhibited dephosphorylation of CDK1 substrates [50, 51]. Moreover, the inability of Greatwall-
depleted cell- free extracts to enter M-phase was reverted by removal of PP2A-B55 delta [50]. 
It was shown recently by two independent laboratories that a small protein called cAMP-
regulated phosphoprotein-19 (ARPP-19), a close relative of another small protein alfa-
Endosulfine (ENSA), was an ideal substrate for Greatwall kinase in Xenopus laevis cell- free 
extracts [52, 53]. Thus, the network of kinases and phosphatases governing CDK1 substrates 





Several pathways control CDK1 inhibition upon M-phase exit. The major pathway called here 
canonical, involves dissociation of cyclin B from CDK1 and is followed by cyclin B 
degradation and disappearance from the cell. Other, probably minor pathways, including 
phosphorylation and dephosphorylation of CDK1 at different sites, and active inhibition of 
CDK1 kinase activity, may play supplementary role in shortening the process of CDK1 
inactivation. This hypothetical role of CDK1 accelerator could be of particular importance for 
very fast cleaving embryos such as amphibian embryos. CDK2/cyclin E and PKA seem also to 
exercise an important control over the timing of CDK1/cyclin B inactivation. The alternative 
pathways in CDK1/cyclin B inactivation may be important in certain unique conditions when 
the canonical pathway becomes ineffective. For example, in rat one-cell embryos treated with 
MG132 the  M-phase exit probably occurs without cyclin B degradation [54]. Also in mouse 
oocytes undergoing maturation and fertilized in vitro by numerous spermatozoids CDK1/cyclin 
B is inactivated rather via threonine 161 dephosphorylation than full cyclin B degradation [55]. 
Surprisingly, recent studies of the minimal control of CDK network in fission yeast suggest 
that modulation of CDK1 activity and not its proteolytic or phosphorylation-dependent 
regulation could play an ancestral role during evolution [56]. This discovery will certainly 
stimulate further studies on non-canonical pathways regulating M-phase exit and it is possible 
that the canonical pathway will become non-canonical, and vice versa.  
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Legend to the figures: 
 
Fig.1. Regulation of Emi2 association with APC/CCdc20. Phosphorylation sites in the upper 
part of Emi2 are inhibitory for the association and are protected during MII –arrest (green 
arrows and symbols of inhibition), while the sites in the bottom part of Emi2 are activatory for 
the association and the CSF-arrest exit (red arrows). 
 
Fug. 2. Canonical pathway of CDK1/cyclin B inhibition.  
 















  Cyclin B 














  Cyclin B 
  CDK1 
 
P 






Myt1 or    
Wee1 
Transitional  
inhibitory phosphorylation of CDK1  
on Tyr 15 & Thr 14 






inhibition of CDK1  
